This site is intended for healthcare professionals
News

Health Canada approves Ziextenzo (pegfilgrastim, reference biologic drug: Neulasta) and Riximyo (rituximab, reference biologic drug: Rituxan) for marketing in Canada. Sandoz Canada

Read time: 1 mins
Last updated:10th Jun 2020
Published:10th Jun 2020
Condition: Neutropenia
Type: drug
Register free for full access to medthority.com